Key facts
- Atelerix’s last known valuation is $4.3M (Feb 2022).
- It has raised $6.6M; the latest was Later Stage VC ($1.5M) in Jan 2025.
- Notable investors include Innovate UK, Future Planet Capital, Cambridge Angels, UK Innovation & Science Seed Fund, ACF Investors — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Atelerix
- ·The full record, as it builds
Funding rounds
No funding rounds for Atelerix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Atelerix
Developer of a cell preservation technology designed to store and transport cells and tissues at room temperature. The company's technology uses alginate hydrogels to encapsulate biological products and protect them from biochemical and physical damage during storage and shipment, enabling doctors and surgeons to keep the products safe during storage and transport.
- Sector
- Healthcare
- HQ
- Newcastle upon Tyne, United Kingdom
- Founded
- 2017
- Employees
- 10
- Website
- atelerix.co.uk/
- Ownership
- Privately Held (backing)
Atelerix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atelerix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atelerix in its N-PORT filings yet. We sweep new filings monthly.